# Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Study · id `cardio:ct-nct03351478` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03351478](<https://clinicaltrials.gov/study/NCT03351478>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03351478

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 770 participants.

## Technical summary

Registry record NCT03351478. Randomized; double masking; primary purpose treatment. Start 2017-11-27 (actual); primary completion 2019-05-16 (actual). Results posted on 2021-05-11.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 770 participants (enrolled count; ClinicalTrials.gov record NCT03351478, source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)
- Started: 2017-11-27 (actual) (ClinicalTrials.gov record NCT03351478, source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)
- Primary completion: 2019-05-16 (actual) (ClinicalTrials.gov record NCT03351478, source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)
- Completion: 2019-05-16 (actual) (ClinicalTrials.gov record NCT03351478, source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)
- Results first posted: 2021-05-11 (ClinicalTrials.gov record NCT03351478, source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Canada; Czechia; France; Italy; Latvia; Mexico; Russia; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT03351478, source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03351478-2021-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
- Acronym: SOTA-EMPA
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sotagliflozin
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Lead sponsor: Lexicon Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 338de4d0fbbf72842f7a61bcfefeb30e65238b5dc08c4614d26be2356c3da002
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
